List view / Grid view
18 December 2015 | By Victoria White
Explaining his reasoning behind the company name change, Stanley Crooke, CEO of Ionis, told Forbes: “My underlying concern was that the name was a distraction"...
30 October 2015 | By Victoria White
The Phase 2 study is intended to further characterise the profile of ISIS-FXI Rx and will provide essential data for Bayer's future clinical development programme for ISIS-FXI Rx...
9 September 2013 | By Biogen Idec
Biogen Idec and Isis Pharmaceuticals, Inc. announced that the companies have entered into a broad, multi-year collaboration...
29 January 2013 | By Sanofi
“Today’s FDA approval of KYNAMRO is great news..."
14 December 2012 | By Sanofi
"We are disappointed by the Committee's recommendation..."
11 December 2012 | By AstraZeneca
AstraZeneca and Isis Pharmaceuticals, Inc. announced a strategic alliance...
18 October 2012 | By Sanofi
"We are very encouraged by the support for KYNAMRO..."
29 June 2012 | By Biogen Idec
Isis expands its rare disease franchise to include DM1...
4 January 2012 | By Biogen Idec
Biogen Idec and Isis Pharmaceuticals, Inc. have entered into an exclusive, worldwide option and collaboration agreement...
